Drugs / cytotoxic lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01782287 | Dec 2012 → Dec 2018 | metastatic neoplasm | NeuroVita Clinic | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2/3 | NCT01759810 Background | Dec 2012 → Dec 2018 | glioblastoma | NeuroVita Clinic | Unknown | No outcome recorded |
| Phase 2/3 | NCT01782274 Comparator | Dec 2012 → Dec 2018 | metastatic neoplasm | NeuroVita Clinic | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cytotoxic lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01782287 ↗ |
| Action | Deplete | “Preparation of CTLs aims to enhance cytotoxic effect on tumor due to great number of circulating CTLs.” NCT01782287 ↗ |
| Modality | Cell therapy | “cytotoxic lymphocytes” NCT01759810 ↗ |
| Route | Intrathecal | “Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months” NCT01759810 ↗ |